<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Williams</td>
<td>VP, General Counsel and Chief Compliance Officer</td>
<td>Introduction</td>
</tr>
<tr>
<td>Patrick S. Williams</td>
<td>President &amp; CEO</td>
<td>Business Update</td>
</tr>
<tr>
<td>Ian Cleminson</td>
<td>Executive Vice President &amp; CFO</td>
<td>Financial Performance</td>
</tr>
<tr>
<td>Patrick S. Williams</td>
<td>President &amp; CEO</td>
<td>Closing Comments</td>
</tr>
</tbody>
</table>

Q&A
FORWARD LOOKING STATEMENTS

This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like “expects,” “estimates,” “anticipates,” “may,” “believes,” “feels” or similar words or expressions), for example, which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec's Annual Report on Form 10-K for the year ended December 31, 2016 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors" in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
USE OF NON-GAAP FINANCIAL MEASURES

The information presented in this presentation includes financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles in the United States (GAAP). These non-GAAP financial measures comprise adjusted EBITDA, income before income taxes excluding special items, net income excluding special items and related per share amounts together with net debt. Adjusted EBITDA is net income per our consolidated financial statements adjusted for the exclusion of charges for interest expense, net, income taxes, depreciation, amortization and acquisition fair value adjustments. Income before income taxes, net income and diluted EPS, excluding special items, per our consolidated financial statements are adjusted for the exclusion of amortization of acquired intangible assets, foreign exchange loss on liquidation of subsidiary, fair value acquisition accounting, foreign currency exchange losses, adjustment to fair value of contingent consideration and loss on disposal of subsidiary. Net debt is total debt less cash and cash equivalents. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures are provided herein and in the appendices below. The Company believes that such non-GAAP financial measures provide useful information to investors and may assist them in evaluating the Company’s underlying performance and identifying operating trends. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and the Company has determined that it is appropriate to make this data available to all investors. While the Company believes that such measures are useful in evaluating the Company’s performance, investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP. In addition, these non-GAAP financial measures may differ from similarly-titled non-GAAP financial measures used by other companies and do not provide a comparable view of the Company’s performance relative to other companies in similar industries. Management uses adjusted EPS (the most directly comparable GAAP financial measure for which is GAAP EPS) and adjusted net income and adjusted EBITDA (the most directly comparable GAAP financial measure for which is GAAP net income) to allocate resources and evaluate the performance of the Company’s operations. Management believes the most directly comparable GAAP financial measure is GAAP net income and has provided a reconciliation of adjusted EBITDA and net income excluding special items, and related per share amounts, to GAAP net income herein and in the appendices below.

© 2017. All Rights Reserved. Innospec, Inc.
### SUMMARY OF 1ST QUARTER PERFORMANCE

- **Great start to 2017 – very strong quarter**
- **Sales up 39 percent; adjusted EBITDA up 20 percent**
- **Adjusted EPS of $1.00; 8 percent increase on Q1 2016**
- **Significant sales growth and profit improvement in Oilfield Services**
- **Return to solid volume growth in Fuel Specialties**
- **Performance Chemicals growth continues – good start for acquisition**
- **Octane Additives – over $13 million of sales moved into Q2**
Q1 2017 CONSOLIDATED RESULTS

($ in millions)

- Sales up 39 percent; Like-for-like sales up 11 percent
- Adjusted EPS of $1.00; up 8 percent
Good volume growth – notably in the Americas

Gross margin starting to normalize compared to a strong Q4 2016

Operating income and adjusted EBITDA up 12 percent
Q1 2017 PERFORMANCE CHEMICALS
($ in millions)

- **Net Sales**: $34.7M (Q1 '16) to $94.5M (Q1 '17), +172%
- **Gross Margin**: 17.7% (Q1 '16) to 31.1% (Q1 '17), +13.4% pts
- **Operating Income**: $4.4M (Q1 '16) to $6.0M (Q1 '17), +36%
- **Adjusted EBITDA**: $5.9M (Q1 '16) to $11.8M (Q1 '17), +100%

- Significant positive impact of acquisition from Huntsman
- Gross margins in line with expectations
- Adjusted EBITDA doubles year over year
Increased customer activity driving sales growth

Gross profit and margins up on Q1 2016, but broadly flat sequentially

Continued its' profitable recovery as expected
Q1 2017 OCTANE ADDITIVES

($ in millions)

- 61%  - 27.2% pts  - 82%  - 80%

- New $20 million order; only partly fulfilled in Q1 2017
- Operating income of $2.0 million; compared to $11.0 million in Q1 2016
- Balance of order (over $13 million) will be delivered in Q2
Q1 2017 CORPORATE ITEMS

- Corporate costs in line with expectations
- Effective tax rate 25.9 percent

<table>
<thead>
<tr>
<th></th>
<th>Q1 2016</th>
<th>Q1 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporate costs</td>
<td>(10.2)</td>
<td>(10.7)</td>
</tr>
<tr>
<td>Pension credit</td>
<td>1.8</td>
<td>1.1</td>
</tr>
<tr>
<td>Effective tax rate</td>
<td>22.9%</td>
<td>25.9%</td>
</tr>
</tbody>
</table>

($ in millions)
Q1 2017 BALANCE SHEET

- Injection of $28.6 million of working capital to acquired business
- Working capital increase drives an operating cash outflow for the quarter
- Leverage remains low

<table>
<thead>
<tr>
<th>($ in millions)</th>
<th>Q4 2016</th>
<th>Q1 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net debt</td>
<td>(171.4)</td>
<td>(198.3)</td>
</tr>
<tr>
<td>Total working capital</td>
<td>180.5</td>
<td>237.6</td>
</tr>
</tbody>
</table>
Very strong start to 2017

All core businesses growing and performing well

Portfolio well balanced

Semi-annual dividend of 38 cents per share

Leverage in good shape

Still receptive to M&A or partnership opportunities
YOUR OPPORTUNITY TO ASK QUESTIONS
Thank you for your continued support

Q2 2017 Results

<table>
<thead>
<tr>
<th>AUGUST 2017</th>
<th>Sun</th>
<th>Mon</th>
<th>Tue</th>
<th>Wed</th>
<th>Thu</th>
<th>Fri</th>
<th>Sat</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>14</td>
<td>15</td>
<td>16</td>
<td>17</td>
<td>18</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>21</td>
<td>22</td>
<td>23</td>
<td>24</td>
<td>25</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>28</td>
<td>29</td>
<td>30</td>
<td>31</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- August 8 - Results Release After Close
- August 9 - Conference Call